[1] Hruby A , Hu F B . The epidemiology of obesity: A big picture. Pharmacoeconomics, 2015, 33(7):673-689.
[2] [2]Aung K, Lorenzo C, Hinojosa M A, et al. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. Clin Endocrinol Metab, 2014, 99(2):462-468.
[3] [3]Bingol Z, Pihtili A, Cagatay P, et al. Clinical predictors of obesity hypoventilation syndrome in obese subjects with obstructive sleep apnea. Respir care, 2015, 60(5):666-672.
[4] [4]Gonzalez A, Hartge P, Cerhan JR, et al. Association between different obesity measures and the risk of stroke in the epic Spanish cohort. Eur J Nutrit, 2015, 54(3):365-375.
[5] [5]Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: will glp-1 agonists end the struggle? World J Hepatol, 2018, 10(11):10-14.
[6] [6]Hedderich D M , Hasenberg T , Haneder S , et al. Effects of bariatric surgery on non-alcoholic fatty liver disease: magnetic resonance imaging is an effective, non-invasive method to evaluate changes in the liver fat fraction. Obes Surg, 2017, 27(7):1755-1762.
[7] [7]Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol, 2013, 28(s1):11-17.
[8] Peterli R. Winerhanssen BK, Peters T. Effect of sleeve gastrectomy vs Roux-en-y gastric bypass on morbid obesity. JAMA, 2018,319(3):255-265.
[9] Taitano AA, Markow M, Finan JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. Gastrointest Surg,2015,19(3):429–436.
[10] Younossi Z M , Koenig A B , Abdelatif D , et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1):73-84.
[11] Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med, 2017,135:277-295.
[12] 赵泽华, 范建高. 2016年美国肝病年会非酒精性脂肪性肝病深度报道. 实用肝脏病杂志, 2017,20(1):21-24.
[13] Kleiner DE, Makhlouf HR. Histology of NAFLD and NASH in adults and children. Clin Liver Dis,2016,20(2):293–312.
[14] Mrad R A , Merjaneh N , Mubarak G M , et al. The increasing burden of nonalcoholic fatty liver disease among young adults in the united states: A growing epidemic. Gastroenterology, 2016, 64(4):1386-1387.
[15] 张强, 孟令隆, 牛吉攀. 非酒精性脂肪性肝病发病相关危险因素分析. 实用肝脏病杂志, 2017,20(6):756-757.
[16] Shuja H , Ahmed M H . Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: A future treatment by choice or by chance. J Obes, 2013, 2013:1-11.
[17] Cazzo E , Laísa Simakawa J, José Carlos P, et al. Effect of Roux-en-y gastric bypass on non-alcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg, 2015, 25(6):982-985.
[18] Abangah G , Yousefi A , Asadollahi R , et al. Correlation of body mass index and serum parameters with ultrasonographic grade of fatty change in non-alcoholic fatty liver disease. Iran Red Crescent Med J, 2014, 16(1):815-815.
[19] Lassailly G, Caiazzo R, Pattou F, et al. Bariatric surgery for curing NASH in the morbidly obese. Hepatology,2013,58(6):1249–1251.
[20] Boutari C, Perakakis N, Mantzoros C S. Association of adipokines with development and progression of non-alcoholic fatty liver disease. Endocrinol Metab, 2018, 33(1):33-43.
[21] Baltieri L, Chaim EA, Chaim FDM, et al. Correlation between nonalcoholic fatty liver disease features and levels of adipokines and inflammatory cytokines among morbidly obese individuals. Arq Gastroenterol,2018 55(3):247-251.
[22] Malin S K, Bena J, Abood B , et al. Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery. Diabet Obes Metabol, 2014,16(12):1230-1238.
[23] Mosinski JD, Pagadala MR, Mulya A, et al. Gastric bypass surgery is protective from high-fat diet-induced non-alcoholic fatty liver disease and hepatic endoplasmic reticulum stress. Acta Physiologica, 2016, 217(2):564-572.
[24] Bower G, Athanasiou T, Isla A M, et al. Bariatric surgery and non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2015, 27(7):755-768.
[25] Liu J, Wang T, He K, et al. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. Eur Rev Med Pharmacol Sci, 2019,23(18):8158-8167.
[26] Huang, XL, Xu M, Chen Y, et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine,2015,94(40):1682.
[27] Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol,2006,6:33.
[28] Runde J, Azzam RK. Hepatobiliary manifestations in systemic disease. Pediatr Ann, 2018,47(11):e458-e464. |